395 related articles for article (PubMed ID: 25907546)
1. Validation of the revised international prognostic scoring system (IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registry.
de Swart L; Smith A; Johnston TW; Haase D; Droste J; Fenaux P; Symeonidis A; Sanz G; Hellström-Lindberg E; Cermák J; Germing U; Stauder R; Georgescu O; MacKenzie M; Malcovati L; Holm MS; Almeida AM; Mądry K; Slama B; Guerci-Bresler A; Sanhes L; Beyne-Rauzy O; Luño E; Bowen D; de Witte T
Br J Haematol; 2015 Aug; 170(3):372-83. PubMed ID: 25907546
[TBL] [Abstract][Full Text] [Related]
2. Improved risk stratification by the integration of the revised international prognostic scoring system with the myelodysplastic syndromes comorbidity index.
van Spronsen MF; Ossenkoppele GJ; Holman R; van de Loosdrecht AA
Eur J Cancer; 2014 Dec; 50(18):3198-205. PubMed ID: 25454415
[TBL] [Abstract][Full Text] [Related]
3. Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database.
Voso MT; Fenu S; Latagliata R; Buccisano F; Piciocchi A; Aloe-Spiriti MA; Breccia M; Criscuolo M; Andriani A; Mancini S; Niscola P; Naso V; Nobile C; Piccioni AL; D'Andrea M; D'Addosio A; Leone G; Venditti A
J Clin Oncol; 2013 Jul; 31(21):2671-7. PubMed ID: 23796988
[TBL] [Abstract][Full Text] [Related]
4. Prognostic scoring systems for myelodysplastic syndromes (MDS) in a population-based setting: a report from the Swedish MDS register.
Moreno Berggren D; Folkvaljon Y; Engvall M; Sundberg J; Lambe M; Antunovic P; Garelius H; Lorenz F; Nilsson L; Rasmussen B; Lehmann S; Hellström-Lindberg E; Jädersten M; Ejerblad E
Br J Haematol; 2018 Jun; 181(5):614-627. PubMed ID: 29707769
[TBL] [Abstract][Full Text] [Related]
5. High flow cytometric scores identify adverse prognostic subgroups within the revised international prognostic scoring system for myelodysplastic syndromes.
Alhan C; Westers TM; Cremers EM; Cali C; Witte BI; Ossenkoppele GJ; van de Loosdrecht AA
Br J Haematol; 2014 Oct; 167(1):100-9. PubMed ID: 24976502
[TBL] [Abstract][Full Text] [Related]
6. Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM).
Della Porta MG; Tuechler H; Malcovati L; Schanz J; Sanz G; Garcia-Manero G; Solé F; Bennett JM; Bowen D; Fenaux P; Dreyfus F; Kantarjian H; Kuendgen A; Levis A; Cermak J; Fonatsch C; Le Beau MM; Slovak ML; Krieger O; Luebbert M; Maciejewski J; Magalhaes SM; Miyazaki Y; Pfeilstöcker M; Sekeres MA; Sperr WR; Stauder R; Tauro S; Valent P; Vallespi T; van de Loosdrecht AA; Germing U; Haase D; Greenberg PL; Cazzola M
Leukemia; 2015 Jul; 29(7):1502-13. PubMed ID: 25721895
[TBL] [Abstract][Full Text] [Related]
7. Prognostic relevance of morphological classification models for myelodysplastic syndromes in an era of the revised International Prognostic Scoring System.
van Spronsen MF; Ossenkoppele GJ; Westers TM; van de Loosdrecht AA
Eur J Cancer; 2016 Mar; 56():10-20. PubMed ID: 26798967
[TBL] [Abstract][Full Text] [Related]
8. Improving Revised International Prognostic Scoring System Pre-Allogeneic Stem Cell Transplantation Does Not Translate Into Better Post-Transplantation Outcomes for Patients with Myelodysplastic Syndromes: A Single-Center Experience.
Alzahrani M; Power M; Abou Mourad Y; Barnett M; Broady R; Forrest D; Gerrie A; Hogge D; Nantel S; Sanford D; Song K; Sutherland H; Toze C; Nevill T; Narayanan S
Biol Blood Marrow Transplant; 2018 Jun; 24(6):1209-1215. PubMed ID: 29474870
[TBL] [Abstract][Full Text] [Related]
9. Dichotomization of the new revised international prognostic scoring system for a better clinical stratification of patients with myelodysplastic syndromes.
Montoro J; Pomares H; Villacampa G; Merchán B; Molero A; Alonso E; Gallur L; Grau J; Salamero O; Roldán E; Saumell S; Ortega M; Sureda A; Bosch F; Arnan M; Valcárcel D
Leuk Lymphoma; 2019 Jun; 60(6):1522-1527. PubMed ID: 30499738
[TBL] [Abstract][Full Text] [Related]
10. Enumerating bone marrow blasts from nonerythroid cellularity improves outcome prediction in myelodysplastic syndromes and permits a better definition of the intermediate risk category of the Revised International Prognostic Scoring System (IPSS-R).
Calvo X; Arenillas L; Luño E; Senent L; Arnan M; Ramos F; Pedro C; Tormo M; Montoro J; Díez-Campelo M; Blanco ML; Arrizabalaga B; Xicoy B; Bonanad S; Jerez A; Nomdedeu M; Ferrer A; Sanz GF; Florensa L
Am J Hematol; 2017 Jul; 92(7):614-621. PubMed ID: 28370234
[TBL] [Abstract][Full Text] [Related]
11. Use of newer prognostic indices for patients with myelodysplastic syndromes in the low and intermediate-1 risk categories: a population-based study.
Valcárcel D; Sanz G; Ortega M; Nomdedeu B; Luño E; Diez-Campelo M; Ardanaz MT; Pedro C; Montoro J; Collado R; Andreu R; Marco V; Cedena MT; de Paz R; Tormo M; Xicoy B; Ramos F; Bargay J; Gonzalez B; Brunet S; Muñoz JA; Gomez V; Bailén A; Sanchez J; Merchán B; del Cañizo C; Vallespí T;
Lancet Haematol; 2015 Jun; 2(6):e260-6. PubMed ID: 26688236
[TBL] [Abstract][Full Text] [Related]
12. Dynamic assessment of RBC-transfusion dependency improves the prognostic value of the revised-IPSS in MDS patients.
Hiwase DK; Singhal D; Strupp C; Chhetri R; Kutyna MM; Wee LA; Harrison PB; Nath SV; Wickham N; Hui CH; Gray JX; Bardy P; Ross DM; Lewis ID; Reynolds J; To LB; Germing U
Am J Hematol; 2017 Jun; 92(6):508-514. PubMed ID: 28247421
[TBL] [Abstract][Full Text] [Related]
13. Overall survival in lower IPSS risk MDS by receipt of iron chelation therapy, adjusting for patient-related factors and measuring from time of first red blood cell transfusion dependence: an MDS-CAN analysis.
Leitch HA; Parmar A; Wells RA; Chodirker L; Zhu N; Nevill TJ; Yee KWL; Leber B; Keating MM; Sabloff M; St Hilaire E; Kumar R; Delage R; Geddes M; Storring JM; Kew A; Shamy A; Elemary M; Lenis M; Mamedov A; Ivo J; Francis J; Zhang L; Buckstein R
Br J Haematol; 2017 Oct; 179(1):83-97. PubMed ID: 28677895
[TBL] [Abstract][Full Text] [Related]
14. [The application of a new prognostic score system for 435 cases of primary myelodysplastic syndrome diagnosed with WHO classification].
Wang XQ;
Zhonghua Nei Ke Za Zhi; 2009 Aug; 48(8):633-7. PubMed ID: 19954053
[TBL] [Abstract][Full Text] [Related]
15. Validation of the Revised International Prognostic Scoring System for patients with myelodysplastic syndromes.
Savic A; Marisavljevic D; Kvrgic V; Stanisavljevic N
Acta Haematol; 2014; 131(4):231-8. PubMed ID: 24335346
[TBL] [Abstract][Full Text] [Related]
16. Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs de novo myelodysplastic syndromes: a report on behalf of the MDS Clinical Research Consortium.
Zeidan AM; Al Ali N; Barnard J; Padron E; Lancet JE; Sekeres MA; Steensma DP; DeZern A; Roboz G; Jabbour E; Garcia-Manero G; List A; Komrokji R
Leukemia; 2017 Jun; 31(6):1391-1397. PubMed ID: 28111463
[TBL] [Abstract][Full Text] [Related]
17. IPSS-R in 555 Taiwanese patients with primary MDS: Integration of monosomal karyotype can better risk-stratify the patients.
Yang YT; Hou HA; Liu CY; Lin CC; Chou WC; Lee FY; Liu MC; Liu CW; Tang JL; Yao M; Li CC; Kuo YY; Huang SY; Ko BS; Chen CY; Hsu SC; Lin CT; Wu SJ; Tsay W; Chen YC; Tien HF
Am J Hematol; 2014 Sep; 89(9):E142-9. PubMed ID: 24845799
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort study.
Efficace F; Gaidano G; Breccia M; Voso MT; Cottone F; Angelucci E; Caocci G; Stauder R; Selleslag D; Sprangers M; Platzbecker U; Ricco A; Sanpaolo G; Beyne-Rauzy O; Buccisano F; Palumbo GA; Bowen D; Nguyen K; Niscola P; Vignetti M; Mandelli F
Lancet Oncol; 2015 Nov; 16(15):1506-1514. PubMed ID: 26404501
[TBL] [Abstract][Full Text] [Related]
19. Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides.
Zeidan AM; Sekeres MA; Garcia-Manero G; Steensma DP; Zell K; Barnard J; Ali NA; Zimmerman C; Roboz G; DeZern A; Nazha A; Jabbour E; Kantarjian H; Gore SD; Maciejewski JP; List A; Komrokji R;
Leukemia; 2016 Mar; 30(3):649-57. PubMed ID: 26464171
[TBL] [Abstract][Full Text] [Related]
20. Patient-reported outcomes enhance the survival prediction of traditional disease risk classifications: An international study in patients with myelodysplastic syndromes.
Efficace F; Cottone F; Abel G; Niscola P; Gaidano G; Bonnetain F; Anota A; Caocci G; Cronin A; Fianchi L; Breccia M; Stauder R; Platzbecker U; Palumbo GA; Luppi M; Invernizzi R; Bergamaschi M; Borin L; Di Tucci AA; Zhang H; Sprangers M; Vignetti M; Mandelli F
Cancer; 2018 Mar; 124(6):1251-1259. PubMed ID: 29231969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
